|
Nov 9
|
Arcellx Third Quarter 2024 Earnings: Misses Expectations
|
|
Nov 8
|
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
|
|
Nov 7
|
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
|
|
Nov 7
|
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
|
|
Nov 7
|
Arcellx price target raised to $106 from $81 at Morgan Stanley
|
|
Nov 7
|
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
|
|
Nov 5
|
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
|
|
Nov 5
|
Cancer cell therapy from Arcellx, Gilead shows promise in early data
|
|
Oct 9
|
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 22
|
We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth
|
|
Jun 21
|
Arcellx Stock Earns Relative Strength Rating Upgrade
|
|
May 12
|
Arcellx First Quarter 2024 Earnings: Beats Expectations
|
|
May 10
|
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
|
|
May 10
|
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
|
|
May 9
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Arcellx Provides First Quarter 2024 Financial Results
|
|
May 9
|
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
|
|
May 7
|
Arcellx to Participate in Two Upcoming Investor Conferences
|